Orthocell (ASX:OCC) is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.
It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.
The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.
It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.
The firm's shares rallied 14% in early trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.